Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 31 of 77 for:    "Rabies" | "Immunologic Factors"

A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02491541
Recruitment Status : Completed
First Posted : July 8, 2015
Last Update Posted : July 9, 2015
Sponsor:
Information provided by (Responsible Party):
Jiangsu Province Centers for Disease Control and Prevention

Brief Summary:
The purpose of this single-centre, randomized, double-blind, parallel control, phase 3 study is to evaluate the safety and immunogenicity of a rabies vaccine (Vero Cell) for human use in healthy Chinese subjects aged 10-60 years, according to the Essen methods (1-1-1-1-1) vaccination.

Condition or disease Intervention/treatment Phase
Rabies Biological: Changchun Werersai Biological: Jilin Maifeng Phase 3

Detailed Description:
There will be two immunization arms. 1200 healthy subjects will be randomly assigned (1:1) to receive an experimental vaccine or a parallel comparator vaccine. All of them will be received five doses of rabies vaccine at day 0,3,7,14,28 according to the traditional Essen methods (1-1-1-1-1) vaccination.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Single-centre, Randomized, Double-blind, Parallel Control, Phase 3 Study to Evaluate the Safety and Immunogenicity of a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects Aged 10-60 Years
Study Start Date : August 2012
Actual Primary Completion Date : December 2012
Actual Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Rabies

Arm Intervention/treatment
Experimental: Changchun Werersai
A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.
Biological: Changchun Werersai

A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.

1.0 ml experimental vaccine on day 0,3,7,14,28


Active Comparator: Jilin Maifeng
A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.
Biological: Jilin Maifeng

A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.

1.0 ml comparator vaccine on day 0,3,7,14,28





Primary Outcome Measures :
  1. Positive seroconversion rate of serum rabies virus neutralizing antibody 42 days after full vaccination [ Time Frame: 42 days after full vaccination ]

Secondary Outcome Measures :
  1. Geometric mean concentration (GMC) of serum rabies virus neutralizing antibody 42 days after full vaccination [ Time Frame: 42 days after full vaccination ]
  2. Positive seroconversion rate of serum rabies virus neutralizing antibody 14 days after full vaccination [ Time Frame: 14 days after full vaccination ]
  3. Geometric mean concentration (GMC) of serum rabies virus neutralizing antibody 14 days after full vaccination [ Time Frame: 14 days after full vaccination ]
  4. Incidence of local and systemic adverse reactions during safety observation period after each vaccination [ Time Frame: 0-7 days after each vaccination and 8-28 days after the fifth vaccination ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   10 Years to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Aged from 10 to 60 years old
  • Subjects or legal guardians can and will comply with the requirements of the protocol
  • Subjects or legal guardians are able to understand and sign the informed consent
  • Healthy subjects judged from medical history after investigator's inquiry
  • Subjects with temperature <=37.0°C on axillary setting

Exclusion Criteria:

  • Female in lactation or pregnancy, or plan to be pregnant during the study period
  • Subject who has allergic history to any vaccine or other medicines
  • Subject who has injury history by dogs or other mammals and has been vaccinated with rabies vaccine
  • Subject who has serious adverse reaction history after vaccination such as allergies, hives, difficulty in breathing, angioedema or abdominal pain
  • Subject with congenital malformation, developmental disorder or serious chronic disease
  • Subject with autoimmune diseases or immunodeficiency
  • Subject with asthma, unstable over the past two years requiring emergency treatment, hospitalization, intubation, oral or intravenous corticosteroids
  • Subject with diabetes (Type I or II) excluding gestational diabetes
  • Subject with thyroidectomy history, or require treatment in the past 12 months due to thyroid disease
  • Subject with severe angioedema in the past 3 years or require treatment in the past 2 years
  • Subject with hypertension and with a blood pressure exceeding 145/95 mmHg at enrollment time
  • Subject with coagulation abnormalities diagnosed by doctors (such as clotting factor deficiency, coagulation disorders, platelet disorder) or obvious bruises or blood clotting disorder
  • Subject with cancer, or has been treated in active cancer period or not clearly cured, or may recur during the study period
  • Subject with epilepsy, excluding those alcohol epilepsy within three years before quitting drinking or those do not need treatment in the past 3 years
  • Asplenia, functional asplenia, without a spleen or removal of the spleen caused by any situation
  • Guillain-Barre syndrome
  • Any prior administration of immunodepressant or corticosteroids in last 6 months
  • Any prior administration of blood products in last 3 months
  • Any prior administration of other research medicine/vaccine in last 30 days
  • Any prior administration of any attenuated live vaccine in last 30 days
  • Any prior administration of subunit or inactivated vaccines in last 14 days, such as pneumococcal vaccine
  • Ongoing anti-tuberculosis prevention or treatment
  • Subject who cannot comply with the trial requirements, or with mental illness/ dual-stage affective psychosis in the past or at present; or has not been controlled and needs to take psychiatric drugs the past 2 years; or with suicidal tendencies in the past 5 years
  • Any medical, psychological, social or other condition judged by investigator, that may interfere subject's compliance with the protocol or signature on informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02491541


Locations
Layout table for location information
China, Jiangsu
Xinyi Center for Disease Control and Prevention
Xuzhou, Jiangsu, China, 221400
Sponsors and Collaborators
Jiangsu Province Centers for Disease Control and Prevention
Investigators
Layout table for investigator information
Principal Investigator: Yuemei Hu Jiangsu Provincial Center for Diseases Control and Prevention

Layout table for additonal information
Responsible Party: Jiangsu Province Centers for Disease Control and Prevention
ClinicalTrials.gov Identifier: NCT02491541     History of Changes
Other Study ID Numbers: 20120002
First Posted: July 8, 2015    Key Record Dates
Last Update Posted: July 9, 2015
Last Verified: July 2015

Additional relevant MeSH terms:
Layout table for MeSH terms
Rabies
Rhabdoviridae Infections
Mononegavirales Infections
RNA Virus Infections
Virus Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs